UPDATE: Credit Suisse Initiates Alkermes at Neutral; Looking For Better Entry
Posted on January 17, 2013 at 13:12 PM EST
Credit Suisse initiated coverage on Alkermes (NASDAQ: ALKS ) with a Neutral rating and a $24.00 price target. Credit Suisse said, "ALKS has an attractive long-term story, but we initiate at Neutral given the potential for a better entry point. Considering ALKS is up 21% YTD (Biotech up 7%, Pharma